|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115548 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-29 08:45:02 |
|
注册时间: Date of Registration: |
2025-12-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
脑卒中后不同高压氧疗干预策略下的上肢功能结局及作用机制研究:一项开放性优效性随机对照研究 |
|
Public title: |
Study on Upper Limb Functional Outcomes and Mechanisms Under Different Hyperbaric Oxygen Therapy Strategies After Stroke: An Open-Label Superiority Randomized Controlled Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑卒中后不同高压氧疗干预策略下的上肢功能结局及作用机制研究:一项开放性优效性随机对照研究 |
|
Scientific title: |
Study on Upper Limb Functional Outcomes and Mechanisms Under Different Hyperbaric Oxygen Therapy Strategies After Stroke: An Open-Label Superiority Randomized Controlled Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林强 |
研究负责人: |
林强 |
|
Applicant: |
Qiang Lin |
Study leader: |
Qiang Lin |
|
申请注册联系人电话: Applicant telephone: |
+86 189 2249 7674 |
研究负责人电话:
Study leader's |
+86 189 2249 7674 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
linqiang@sysush.com |
研究负责人电子邮件: Study leader's E-mail: |
linqiang@sysush.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
研究负责人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
|
Applicant address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China |
Study leader's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China |
|
申请注册联系人邮政编码: Applicant postcode: |
518107 |
研究负责人邮政编码: Study leader's postcode: |
518107 |
|
申请人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Applicant's institution: |
The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen) |
||
|
研究负责人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Affiliation of the Leader: |
The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2025-357-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第七医院(深圳)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-25 00:00:00 | ||
|
伦理委员会联系人: |
魏嘉亿 |
||
|
Contact Name of the ethic committee: |
Jiayi Wei |
||
|
伦理委员会联系地址: |
广东省深圳市光明区新湖街道圳美社区海鑫光高新工业园F栋1楼 |
||
|
Contact Address of the ethic committee: |
1st Floor, Building F, Haixinguang High-tech Industrial Park, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 8120 7260 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第七医院(深圳) |
||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市光明区新湖街道圳园路628号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中山大学附属第七医院 735 项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The 735 Project of the Seventh Affiliated Hospital of Sun Yat-sen University |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.验证高压氧疗联合常规康复治疗改善脑卒中后上肢运动功能的有效性,并进一步明确不同高压氧疗方案的优效性 2.验证高压氧疗联合常规康复治疗可有效改善脑卒中后患者的功能结局 3.探究不同高压氧疗方案对于不同疾病阶段的脑卒中后患者功能结局影响的脑重塑机制 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To verify the effectiveness of hyperbaric oxygen therapy combined with conventional rehabilitation in improving upper limb motor function after stroke, and to further determine the superiority of different hyperbaric oxygen therapy protocols. 2. To confirm that hyperbaric oxygen therapy combined with conventional rehabilitation can effectively improve the functional outcomes of stroke patients. 3. To explore the brain remodeling mechanisms by which different hyperbaric oxygen therapy protocols affect the functional outcomes of stroke patients at various stages of the disease. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 符合全国第四次脑血管病学术会议制订的脑卒中(包括脑出血和脑梗死)诊断标准; 2. 首次发病,并经头颅CT或MRI检查确诊为脑出血或脑梗死,2周≤病程≤6个月; 3. 年龄在18~80岁之间,包括18岁和80岁,性别不限; 4. 蒙特利尔认知评估量表(Montreal Cognitive Assessment, MoCA)≥18分,能配合完成实验; 5. 生命体征平稳; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for stroke (including cerebral hemorrhage and cerebral infarction) established by the Fourth National Cerebrovascular Disease Academic Conference; 2. First-time occurrence, and confirmed by head CT or MRI to be cerebral hemorrhage or cerebral infarction, with a disease course of 2 weeks to 6 months; 3. Age between 18 and 80 years old, including both 18 and 80 years old, with no gender restrictions; 4. A score of 18 or higher on the Montreal Cognitive Assessment (MoCA), capable of cooperating and completing the experiment; 5. Stable vital signs. |
||||||||||||||||||||||
|
排除标准: |
1. 存在高压氧治疗禁忌证:未处理的气胸、肺大疱、开放性胸部外伤、服用双硫仑类药物或抗肿瘤药物、严重呼吸道感染、严重出血倾向、未控制的癫痫或高热。 2. 有恶性肿瘤、严重心、肝、肺、肾功能不全及内分泌、造血、免疫系统等严重原发性疾病; 3.严重精神疾患等原因导致无法理解指令,且无法配合。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. There are contraindications to hyperbaric oxygen therapy: untreated pneumothorax, pulmonary bullae, open chest trauma, taking disulfiram or anticancer drugs, severe respiratory tract infections, severe bleeding tendencies, uncontrolled epilepsy, or high fever. 2. There are serious primary diseases such as malignant tumors, severe heart, liver, lung, kidney dysfunction, and endocrine, hematopoietic, and immune system disorders; 3. Severe mental illnesses that prevent understanding instructions and cooperation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2030-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-01 00:00:00 至 To 2030-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用SAS 9.4 软件进行分层区组随机化,将符合纳入标准的210名受试者根据疾病阶段即亚急性期和恢复期1:1进行分层,并将分层之后的受试者按照1:1:1区组随机分为3组,分别是低压治疗组、高压治疗组和对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization was performed using SAS 9.4 software with stratified block randomization. A total of 210 eligible participants were stratified 1:1 based on the disease stage, that is, the subacute phase and the recovery phase. After stratification, the participants were randomly assigned in a 1:1:1 block ratio into three groups: the low-pressure treatment group, the high-pressure treatment group, and the control group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |